Songjiang Ma - 27 May 2025 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Reporting relationship: President, Director
Issuer ticker: GYRE
Reported as of: 27 May 2025
Net transaction value: -$26,179
SEC form: 4
Accepted by SEC: 29 May 2025, 16:01:09 UTC
Prior SEC filing: 27 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Songjiang Ma

Key filing fact

Songjiang Ma filed Form 4 for GYRE THERAPEUTICS, INC. (GYRE) on 29 May 2025.

Key facts

This page summarizes Songjiang Ma's Form 4 filing for GYRE THERAPEUTICS, INC. (GYRE).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 29 May 2025, 16:01.

Change

Previous filing in this sequence was filed on 27 May 2025.
Current net transaction value: -$26,179.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001985547 Primary reporting owner

Ma Songjiang

Relationship: President, Director
Address: C/O GYRE THERAPEUTICS, INC., 12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Signature: /s/ Songjiang Ma
Signature date: 29 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GYRE transaction

Common Stock

Sale

Transaction value: $20,560
Shares: -2,000
Change %: -0.07%
Price: $10.28
Shares after: 2,806,642
Date: 27 May 2025
Ownership: By Spouse
Footnotes: F1, F2

GYRE transaction

Common Stock

Sale

Transaction value: $5,619
Shares: -558
Change %: -0.02%
Price: $10.07
Shares after: 2,806,084
Date: 28 May 2025
Ownership: By Spouse
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Footnote F2

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F3

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.